| Literature DB >> 18832706 |
Chris Ka-fai Li1, Hao Wu, Huiping Yan, Shiwu Ma, Lili Wang, Mingxia Zhang, Xiaoping Tang, Nigel J Temperton, Robin A Weiss, Jason M Brenchley, Daniel C Douek, Juthathip Mongkolsapaya, Bac-Hai Tran, Chen-lung Steve Lin, Gavin R Screaton, Jin-lin Hou, Andrew J McMichael, Xiao-Ning Xu.
Abstract
Effective vaccines should confer long-term protection against future outbreaks of severe acute respiratory syndrome (SARS) caused by a novel zoonotic coronavirus (SARS-CoV) with unknown animal reservoirs. We conducted a cohort study examining multiple parameters of immune responses to SARS-CoV infection, aiming to identify the immune correlates of protection. We used a matrix of overlapping peptides spanning whole SARS-CoV proteome to determine T cell responses from 128 SARS convalescent samples by ex vivo IFN-gamma ELISPOT assays. Approximately 50% of convalescent SARS patients were positive for T cell responses, and 90% possessed strongly neutralizing Abs. Fifty-five novel T cell epitopes were identified, with spike protein dominating total T cell responses. CD8(+) T cell responses were more frequent and of a greater magnitude than CD4(+) T cell responses (p < 0.001). Polychromatic cytometry analysis indicated that the virus-specific T cells from the severe group tended to be a central memory phenotype (CD27(+)/CD45RO(+)) with a significantly higher frequency of polyfunctional CD4(+) T cells producing IFN-gamma, TNF-alpha, and IL-2, and CD8(+) T cells producing IFN-gamma, TNF-alpha, and CD107a (degranulation), as compared with the mild-moderate group. Strong T cell responses correlated significantly (p < 0.05) with higher neutralizing Ab. The serum cytokine profile during acute infection indicated a significant elevation of innate immune responses. Increased Th2 cytokines were observed in patients with fatal infection. Our study provides a roadmap for the immunogenicity of SARS-CoV and types of immune responses that may be responsible for the virus clearance, and should serve as a benchmark for SARS-CoV vaccine design and evaluation.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18832706 PMCID: PMC2683413 DOI: 10.4049/jimmunol.181.8.5490
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422